

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7376357

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SPARX THERAPEUTICS, INC.	05/06/2022
RECEIVING PARTY DATA		
Name:	SPARX BIOSCIENCE LIMITED	
Street Address:	VISTRA CORPORATE SERVICES CENTRE, WICKHAMS CAY II	
City:	ROAD TOWN, TORTOLA	
State/Country:	VIRGIN ISLANDS, BRITISH	
Postal Code:	VG1110	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Application Number:	63040698	
Application Number:	17350525	
PCT Number:	US2021037818	
Application Number:	63211794	
Application Number:	62786012	
Application Number:	16727554	
CORRESPONDENCE DATA		
Fax Number:	(617)535-3800	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(617)535-3986	
Email:	atriggs@mwe.com, IPDocketBoston@mwe.com	
Correspondent Name:	MCDERMOTT WILL & EMERY	
Address Line 1:	200 CLARENDON STREET, 58TH FLOOR	
Address Line 4:	BOSTON, MASSACHUSETTS 02116-5021	
ATTORNEY DOCKET NUMBER:	112124-0012, ET AL.	
NAME OF SUBMITTER:	ANTHONY TRIGGS	
SIGNATURE:	/Anthony Triggs/	
DATE SIGNED:	06/10/2022	
Total Attachments: 5		

source=112124 - Assignment from Sparx Therapeutics to SparX Bioscience - FINAL#page1.tif
source=112124 - Assignment from Sparx Therapeutics to SparX Bioscience - FINAL#page2.tif
source=112124 - Assignment from Sparx Therapeutics to SparX Bioscience - FINAL#page3.tif
source=112124 - Assignment from Sparx Therapeutics to SparX Bioscience - FINAL#page4.tif
source=112124 - Assignment from Sparx Therapeutics to SparX Bioscience - FINAL#page5.tif

ASSIGNMENT

This ASSIGNMENT is entered into by and between **Sparx Therapeutics, Inc.** ("Assignor"), having its principal place of business at 700E. Business Center Drive, Mt. Prospect, Illinois 60056, U.S. and **SparX Bioscience Limited** ("Assignee"), having its principal place of business at Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, said Assignor does hereby sell, assign, transfer and set over to the said Assignee, the entire right, title and interest in the patent and patent application listed in the attached **Schedule A**, in and to said patent and application for all original, divisional, continuation, continuation-in-part, substitute or reissue applications and patents applied for or granted therefore in the United States of America and in any non-US countries, and the Commissioner of Patents and Trademarks is hereby authorized and requested to issue all such pending applications to said Assignee herein, as assignee of the entire interest therein; and the undersigned for itself and its legal representatives, heirs and assigns does hereby agree and covenant without further remuneration, to execute and deliver all divisional, continuation, continuation-in-part, reissue and other applications for Letters Patent and all assignments thereof to said Assignee or its assigns, to communicate to said Assignee or its representatives all facts known to the undersigned respecting inventions disclosed and claimed in the patent and patent application listed on **Schedule A** whenever requested, to testify in any interferences or other legal proceedings in which said application or patent may become involved, to sign all lawful papers, make all rightful oaths, and do generally everything necessary to aid said Assignee, its successors, assigns and nominees to obtain patent protection for inventions disclosed and claimed in the patent and patent application in the United States of America and in any non-US countries.

This instrument is executed under seal and signed under the pains and penalties of perjury under the laws of the United States of America.

Date: May 06, 2022

Signature: _____

Name: GUIDONG ZHU

Title: PRESIDENT

Assignor: **Sparx Therapeutics, Inc.**

Witness:

May 06, 2022
Date

Signature _____

Name: Qian Chen

Address: 700 E. business center Dr.
Mt. Prospect, IL 60056

Witness:

May 06, 2022
Date

Signature _____

Name: Brandon Williams

Address: 700 E. business center Dr.
Mt. Prospect, IL 60056

Date: May 06, 2022

Signature: _____

Guidong Zhu

Name: GUIDONG ZHU

Title: BOARD DIRECTOR

Assignee: SparX Bioscience Limited

Witness:

May 06, 2022
Date

Qian Chen
Signature

Name: Qian Chen

Address: 700 E. business center Dr.
Mt. Prospect, IL 60056

Witness:

May 06, 2022
Date

Brandon Williams
Signature

Name: Brandon Williams

Address: 700 E. business center Dr.
Mt. Prospect, IL 60056

SCHEDULE A

Country	Application Number	Date Filed	Patent No.	Title
U.S.	63/040,698	June 18, 2020		BISPECIFIC ANTIBODIES TARGETING HUMAN CLAUDIN 18.2 AND PROGRAMMED DEATH-LIGAND 1 (PD-L1)
U.S.	17/350,525	June 17, 2021		BISPECIFIC ANTIBODIES TARGETING HUMAN CLAUDIN 18.2 AND PROGRAMMED DEATH-LIGAND 1 (PD-L1)
PCT	PCT/US2021/037818	June 17, 2021		BISPECIFIC ANTIBODIES TARGETING HUMAN CLAUDIN 18.2 AND PROGRAMMED DEATH-LIGAND 1 (PD-L1)
U.S.	63/211,794	June 17, 2021		ANTI-PDL1 ANTIBODIES AND USES THEREOF
U.S.	62/786,012	December 28, 2018		DISCOVERY OF BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2 FOR THE TREATMENT OF CANCER AND OTHER DISEASES
U.S.	16/727,554	December 26, 2019		BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES
PCT	PCT/US2019/068591	December 26, 2019		BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES
CN	CN20198085635.7	December 26, 2019		BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES

EP	EP19902388.8	December 26, 2019		BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES
KR	KR20217023956	December 26, 2019		BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES
JP	2021-538136	December 26, 2019		BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES
US	62/944,006	December 5, 2019		NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF
US	17/099,568	November 16, 2020		NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF
PCT	PCT/US2020/060774	November 16, 2020		NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF